JP2022512735A5 - - Google Patents

Info

Publication number
JP2022512735A5
JP2022512735A5 JP2021521144A JP2021521144A JP2022512735A5 JP 2022512735 A5 JP2022512735 A5 JP 2022512735A5 JP 2021521144 A JP2021521144 A JP 2021521144A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2022512735 A5 JP2022512735 A5 JP 2022512735A5
Authority
JP
Japan
Application number
JP2021521144A
Other languages
Japanese (ja)
Other versions
JPWO2020081920A5 (https=
JP2022512735A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056910 external-priority patent/WO2020081920A1/en
Publication of JP2022512735A publication Critical patent/JP2022512735A/ja
Publication of JP2022512735A5 publication Critical patent/JP2022512735A5/ja
Publication of JPWO2020081920A5 publication Critical patent/JPWO2020081920A5/ja
Priority to JP2024163238A priority Critical patent/JP2025011102A/ja
Withdrawn legal-status Critical Current

Links

JP2021521144A 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法 Withdrawn JP2022512735A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163238A JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747903P 2018-10-19 2018-10-19
US62/747,903 2018-10-19
PCT/US2019/056910 WO2020081920A1 (en) 2018-10-19 2019-10-18 Compositions and methods for treatment of liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163238A Division JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022512735A JP2022512735A (ja) 2022-02-07
JP2022512735A5 true JP2022512735A5 (https=) 2022-10-25
JPWO2020081920A5 JPWO2020081920A5 (https=) 2022-10-25

Family

ID=70284106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521144A Withdrawn JP2022512735A (ja) 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Country Status (9)

Country Link
US (2) US20210388073A1 (https=)
EP (1) EP3866852A4 (https=)
JP (2) JP2022512735A (https=)
KR (1) KR20210081366A (https=)
CN (2) CN120305401A (https=)
AU (1) AU2019361120A1 (https=)
CA (1) CA3117098A1 (https=)
IL (1) IL282251A (https=)
WO (1) WO2020081920A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154648A1 (en) 2019-09-16 2021-03-25 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof
US20220378843A1 (en) * 2019-11-01 2022-12-01 Figene, Llc Fibroblast-based therapy for treatment of sclerosing cholangitis
CN117487010B (zh) * 2022-08-02 2025-02-14 东莞市朋志生物科技有限公司 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒
AU2024232439A1 (en) * 2023-03-03 2025-08-28 Karydo Therapeutix, Inc. Antibody or antigen-binding fragment of same
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法
WO2025179048A2 (en) * 2024-02-20 2025-08-28 Ecogenome Llc Antibodies that bind dach1 and methods of use
CN119331100B (zh) * 2024-10-16 2025-07-25 天津大学 特异性结合25-羟基维生素d的单克隆抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014770A3 (en) * 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
EP1177796B1 (en) * 1999-04-27 2011-04-27 Mitsubishi Tanabe Pharma Corporation Medicament for prevention or therapeutic treatment of liver disease
JPWO2003014345A1 (ja) * 2001-08-08 2004-11-25 味の素株式会社 肝星細胞活性化に関与する遺伝子パネル
CA2801066C (en) * 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
KR20160138580A (ko) * 2014-04-15 2016-12-05 소렌토 쎄라퓨틱스, 인코포레이티드 Wisp1에 결합하는 항원 결합 단백질
AU2015360502A1 (en) * 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US11015196B2 (en) * 2016-05-20 2021-05-25 The General Hospital Corporation Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
JP2022512735A5 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)